Pediatrix Medical Group (NYSE:MD – Get Free Report) and Biocorrx (OTCMKTS:BICX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.
Profitability
This table compares Pediatrix Medical Group and Biocorrx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pediatrix Medical Group | 9.02% | 19.94% | 8.02% |
| Biocorrx | N/A | N/A | -73.40% |
Risk & Volatility
Pediatrix Medical Group has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, Biocorrx has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pediatrix Medical Group | $1.91 billion | 0.97 | $165.39 million | $2.06 | 10.94 |
| Biocorrx | $800,000.00 | 13.71 | -$3.44 million | ($0.16) | -2.36 |
Pediatrix Medical Group has higher revenue and earnings than Biocorrx. Biocorrx is trading at a lower price-to-earnings ratio than Pediatrix Medical Group, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
97.7% of Pediatrix Medical Group shares are owned by institutional investors. 1.8% of Pediatrix Medical Group shares are owned by insiders. Comparatively, 21.4% of Biocorrx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Pediatrix Medical Group and Biocorrx, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pediatrix Medical Group | 0 | 5 | 1 | 0 | 2.17 |
| Biocorrx | 0 | 1 | 0 | 0 | 2.00 |
Pediatrix Medical Group currently has a consensus price target of $22.50, suggesting a potential downside of 0.20%. Given Pediatrix Medical Group’s stronger consensus rating and higher possible upside, research analysts clearly believe Pediatrix Medical Group is more favorable than Biocorrx.
Summary
Pediatrix Medical Group beats Biocorrx on 12 of the 14 factors compared between the two stocks.
About Pediatrix Medical Group
Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians. The company also provides maternal-fetal care services, including inpatient and office-based clinical care to expectant mothers and unborn babies through affiliated maternal-fetal medicine subspecialists, as well as obstetricians and other clinicians, including maternal-fetal nurse practitioners, certified nurse mid-wives, sonographers, and genetic counselors. In addition, it offers pediatric cardiology care services comprising inpatient and office-based pediatric cardiology care of the fetus, infant, child, and adolescent patient with congenital heart defects and acquired heart disease, as well as adults with congenital heart defects through affiliated pediatric cardiologist subspecialists and other related clinical professionals, including pediatric nurse practitioners, echocardiographers, other diagnostic technicians, and exercise physiologists; and specialized cardiac care to the fetus, neonatal and pediatric patients. Further, the company provides other pediatric subspecialty care services, such as pediatric intensivists, pediatric hospitalists, pediatric surgeons, and pediatric ophthalmologists, as well as pediatric ear, nose, and throat physicians, pediatric gastroenterologists; and support services in the areas of hospitals, primarily in the pediatric emergency rooms, labor and delivery areas, and nursery and pediatric departments. The company was formerly known as MEDNAX, Inc. and changed its name to Pediatrix Medical Group, Inc. in July 2022. Pediatrix Medical Group, Inc. was founded in 1979 and is based in Sunrise, Florida.
About Biocorrx
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
